Colchicine for COVID-19: real-time analysis of all 34 studies

Time 2022-07-19 12:59:54

Web Name: Colchicine for COVID-19: real-time analysis of all 34 studies

WebSite: http://www.c19colchicine.com

ID:252770

Keywords:

real,COVID,Colchicine,for

Description:

Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
HomeHomeCOVID-19 treatment studies for ColchicineCOVID-19 treatment studies for ColchicineC19 studies: ColchicineColchicineSelect treatmentSelect treatmentTreatmentsTreatmentsAntiandrogens(meta)Lactoferrin(meta)Aspirin(meta)Melatonin(meta)Bamlaniv../e..(meta)Metformin(meta)Bebtelovimab(meta)Molnupiravir(meta)Bromhexine(meta)N-acetylcys..(meta)Budesonide(meta)Nigella Sativa(meta)Cannabidiol(meta)Nitazoxanide(meta)Casirivimab/i..(meta)Paxlovid(meta)Colchicine(meta)Peg.. Lambda(meta)Conv. Plasma(meta)Povidone-Iod..(meta)Curcumin(meta)Probiotics(meta)Diet(meta)Proxalutamide(meta)Ensitrelvir(meta)Quercetin(meta)Ensovibep(meta)Remdesivir(meta)Exercise(meta)Sleep(meta)Famotidine(meta)Sotrovimab(meta)Favipiravir(meta)Tixagev../c..(meta)Fluvoxamine(meta)Vitamin A(meta)Hydroxychlor..(meta)Vitamin C(meta)Iota-carragee..(meta)Vitamin D(meta)Ivermectin(meta)Zinc(meta)

---

Other TreatmentsGlobal AdoptionHomeShareTweetMeta AnalysisMetaGlobal AdoptionAdoptionSubmit FeedbackFeedbackDownload ImageDownload ImageDownload ImageDownload ImageDownload ImageDownload ImageColchicine COVID-19 studies. Recent:Hunt Cecconi Pimenta Bonifácio Jalal.Colchicine has been officially adoptedfor early treatment in 1 country.Submit updates/corrections.ColchicineAllJul 15Early, Late, PrEP, PEPCovid Analysis (Preprint) (meta analysis)meta-analysisColchicine for COVID-19: real-time meta analysis of 34 studiesDetails • Statistically significant improvements are seen for mortality, ICU admission, hospitalization, and recovery. 21 studies from 21 independent teams in 13 different countries show statistically significant improvements in isolation (12 for..Jul 15Details Source PDF Early, Late, PrEP, PEPEarly, Late, PrEP, PEPColchicine for COVID-19: real-time meta analysis of 34 studiesCovid Analysis (Preprint) (meta analysis)• Statistically significant improvements are seen for mortality, ICU admission, hospitalization, and recovery. 21 studies from 21 independent teams in 13 different countries show statistically significant improvements in isolation (12 for the most serious outcome).• Meta analysis using the most serious outcome reported shows 40%[29‑50%] improvement. Results are slightly worse for Randomized Controlled Trials, similar after exclusions, and similar for peer-reviewed studies. Early treatment is more effective than late treatment. • Results are robust — in exclusion sensitivity analysis 24 of 34 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.• RCT results are less favorable, however they are dominated by the very late stage RECOVERY RCT, for which the results are not generalizable to earlier usage.• While many treatments have some level of efficacy, they do not replace vaccines and other measures to avoid infection. Only 15% of colchicine studies show zero events in the treatment arm. Multiple treatments are typically used in combination, and other treatments may be more effective.• No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used. Denying the efficacy of treatments increases mortality, morbidity, collateral damage, and endemic risk.• All data to reproduce this paper and sources are in the appendix. Other meta analyses for colchicine can be found in [Yasmin, Zein], showing significant improvements for mortality and severity.Covid Analysis et al., 7/15/2022, preprint, 1 author.Share Tweet Submit Corrections or CommentsJun 29EarlyHunt et al., Journal of General Internal Medicine, doi:10.1007/s11606-022-07701-3death, ↓68.0%, p=0.003Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 VeteransDetails Retrospective 26,508 consecutive COVID+ veterans in the USA, showing lower mortality with multiple treatments including colchicine. Treatment was defined as drugs administered ≥50% of the time within 2 weeks post-COVID+, and may be a cont..Jun 29Details Source PDF Early treatment studyEarly treatment studyMedications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 VeteransHunt et al., Journal of General Internal Medicine, doi:10.1007/s11606-022-07701-3Retrospective 26,508 consecutive COVID+ veterans in the USA, showing lower mortality with multiple treatments including colchicine. Treatment was defined as drugs administered ≥50% of the time within 2 weeks post-COVID+, and may be a continuation of prophylactic treatment in some cases, and may be early or late treatment in other cases. Further reduction in mortality was seen with combinations of treatments.risk of death, 68.0% lower, RR 0.32, p = 0.003, treatment 9 of 402 (2.2%), control 1,603 of 26,106 (6.1%), NNT 26, adjusted, day 30.Hunt et al., 6/29/2022, retrospective, USA, North America, peer-reviewed, 8 authors, study period 1 March, 2020 - 10 September, 2020.Share Tweet Submit Corrections or CommentsJun 2LateCecconi et al., Scientific Reports, doi:10.1038/s41598-022-13424-6death, ↓29.4%, p=0.62Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trialDetails RCT 240 hospitalized patients with COVID-19 pneumonia, mean 9 days from the onset of symptoms, showing no significant differences with colchicine treatment. EudraCT 2020-001841-38.Jun 2Details Source PDF Late treatment studyLate treatment studyEfficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trialCecconi et al., Scientific Reports, doi:10.1038/s41598-022-13424-6RCT 240 hospitalized patients with COVID-19 pneumonia, mean 9 days from the onset of symptoms, showing no significant differences with colchicine treatment. EudraCT 2020-001841-38.risk of death, 29.4% lower, RR 0.71, p = 0.62, treatment 7 of 119 (5.9%), control 10 of 120 (8.3%), NNT 41.risk of mechanical ventilation, 49.6% lower, RR 0.50, p = 0.29, treatment 5 of 119 (4.2%), control 10 of 120 (8.3%), NNT 24.risk of ICU admission, 20.8% lower, RR 0.79, p = 0.67, treatment 11 of 119 (9.2%), control 14 of 120 (11.7%), NNT 41.combined NIV/ICU/ventilation/death, 15.3% lower, RR 0.85, p = 0.62, treatment 21 of 119 (17.6%), control 25 of 120 (20.8%), NNT 31, primary outcome.Cecconi et al., 6/2/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, Europe, peer-reviewed, mean age 65.0, 31 authors, study period August 2020 - March 2021, average treatment delay 9.0 days.Share Tweet Submit Corrections or CommentsMay 5LateJalal et al., Indian Journal of Rheumatology, doi:10.4103/injr.injr_264_21hosp. time, ↓24.1%, p=0.009Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trialDetails Open label RCT of colchicine showing improved recovery with treatment. Only the abstract is currently available. Colchicine 0.5mg bid for 14 days.May 5Details Source PDF Late treatment studyLate treatment studyEffectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trialJalal et al., Indian Journal of Rheumatology, doi:10.4103/injr.injr_264_21Open label RCT of colchicine showing improved recovery with treatment. Only the abstract is currently available. Colchicine 0.5mg bid for 14 days.hospitalization time, 24.1% lower, relative time 0.76, p = 0.009, treatment 36, control 44.Excluded in after exclusion results of meta analysis:minimal details provided.Jalal et al., 5/5/2022, Randomized Controlled Trial, Iraq, Middle East, peer-reviewed, 3 authors, study period 8 May, 2021 - 18 June, 2021, trial NCT04867226.Share Tweet Submit Corrections or CommentsApr 28LatePimenta Bonifácio et al., SSRN Electronic Journal, doi:10.2139/ssrn.4095747death, ↓78.9%, p=0.49Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care on the treatment of patients hospitalized with moderate to critical Covid-19: a pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)Details Open label RCT late stage hospitalized patients in Brazil with 14 colchicine and 16 SOC patients, showing lower mortality and improved recovery with treatment, without statistical significance. Authors note that the colchicine group had o..Apr 28Details Source PDF Late treatment studyLate treatment studyEfficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care on the treatment of patients hospitalized with moderate to critical Covid-19: a pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)Pimenta Bonifácio et al., SSRN Electronic Journal, doi:10.2139/ssrn.4095747Open label RCT late stage hospitalized patients in Brazil with 14 colchicine and 16 SOC patients, showing lower mortality and improved recovery with treatment, without statistical significance. Authors note that the colchicine group had one patient with SOFA ≥7 vs. zero for SOC, however both groups had one patient intubated and SOC had more patients not requiring high-flow oxygen (12 vs. 8).risk of death, 78.9% lower, RR 0.21, p = 0.49, treatment 0 of 14 (0.0%), control 2 of 16 (12.5%), NNT 8.0, relative risk is not 0 because of continuity correction due to zero events.risk of no improvement, 84.9% lower, RR 0.15, p = 0.23, treatment 0 of 14 (0.0%), control 3 of 16 (18.8%), NNT 5.3, relative risk is not 0 because of continuity correction due to zero events.Pimenta Bonifácio et al., 4/28/2022, Randomized Controlled Trial, Brazil, South America, peer-reviewed, 20 authors, trial NCT04724629.Share Tweet Submit Corrections or CommentsApr 12LateGorial et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593death, ↓66.7%, p=0.62Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infectionDetails RCT with 80 colchicine and 80 control patients, showing improved recovery with treatment. SOC included vitamin C, vitamin D, and zinc.Apr 12Details Source PDF Late treatment studyLate treatment studyRandomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infectionGorial et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593RCT with 80 colchicine and 80 control patients, showing improved recovery with treatment. SOC included vitamin C, vitamin D, and zinc.risk of death, 66.7% lower, RR 0.33, p = 0.62, treatment 1 of 80 (1.2%), control 3 of 80 (3.8%), NNT 40.risk of no recovery, 62.8% lower, HR 0.37, p < 0.001, treatment 80, control 80, Cox proportional hazards.Gorial et al., 4/12/2022, Randomized Controlled Trial, Iraq, Middle East, peer-reviewed, 6 authors.Share Tweet Submit Corrections or CommentsApr 5MetaYasmin et al., PLOS ONE, doi:10.1371/journal.pone.0266245 (meta analysis)meta-analysisSafety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trialsDetails Meta analysis of 5 colchicine RCTs (currently there are RCTs) finding that treatment significantly reduced COVID-19 severity.Apr 5Details Source PDF MetaMetaSafety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trialsYasmin et al., PLOS ONE, doi:10.1371/journal.pone.0266245 (meta analysis)Meta analysis of 5 colchicine RCTs (currently there are 17 RCTs) finding that treatment significantly reduced COVID-19 severity.Yasmin et al., 4/5/2022, peer-reviewed, 9 authors.Share Tweet Submit Corrections or CommentsMar 21PrEPPEPOztas et al., Journal of Medical Virology, doi:10.1002/jmv.27731hosp., ↑406.3%, p=0.12Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or HydroxychloroquineDetails Retrospective 635 HCQ users and 643 household contacts, showing higher risk with colchicine in unadjusted results. Patients with conditions leading to the use of colchicine may have significantly different baseline risk, e.g. .Mar 21Details Source PDF Prophylaxis studyProphylaxis studyFrequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or HydroxychloroquineOztas et al., Journal of Medical Virology, doi:10.1002/jmv.27731Retrospective 635 HCQ users and 643 household contacts, showing higher risk with colchicine in unadjusted results.Patients with conditions leading to the use of colchicine may have significantly different baseline risk, e.g. [Topless].1.Topless et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-X,Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study,https://www.thelancet.com/journals../PIIS2665-9913(21)00401-X/fulltext.risk of hospitalization, 406.3% higher, RR 5.06, p = 0.12, treatment 5 of 635 (0.8%), control 1 of 643 (0.2%).risk of symptomatic case, 72.7% higher, RR 1.73, p = 0.07, treatment 29 of 635 (4.6%), control 17 of 643 (2.6%).risk of case, 24.4% higher, RR 1.24, p = 0.35, treatment 43 of 635 (6.8%), control 35 of 643 (5.4%).Excluded in after exclusion results of meta analysis:excessive unadjusted differences between groups.Oztas et al., 3/21/2022, retrospective, Turkey, Europe, peer-reviewed, 15 authors.Share Tweet Submit Corrections or CommentsFeb 2LatePourdowlat et al., Phytotherapy Research, doi:10.1002/ptr.7319hosp., ↓72.8%, p=0.004Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trialDetails RCT 202 patients in Iran, 102 treated with colchicine, showing lower hospitalization and improved clinical outcomes with treatment.Feb 2Details Source PDF Late treatment studyLate treatment studyEfficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trialPourdowlat et al., Phytotherapy Research, doi:10.1002/ptr.7319RCT 202 patients in Iran, 102 treated with colchicine, showing lower hospitalization and improved clinical outcomes with treatment.risk of hospitalization, 72.8% lower, RR 0.27, p = 0.004, treatment 5 of 102 (4.9%), control 18 of 100 (18.0%), NNT 7.6.relative improvement in dyspnea, 37.5% better, RR 0.62, p = 0.03, treatment 89, control 63, excluding 5 treatment and 37 control patients that needed hospitalization/other interventions.relative improvement in Ct score, 22.4% better, RR 0.78, p = 0.048, treatment 89, control 63, excluding 5 treatment and 37 control patients that needed hospitalization/other interventions.Pourdowlat et al., 2/2/2022, Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 18 authors.Share Tweet Submit Corrections or CommentsJan 31LateKarakaş et al., The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924death, ↓12.7%, p=0.72Reducing length of hospital stay with colchicineDetails Retrospective 356 hospitalized COVID-19 patients, shorter hospitalization time with colchicine treatment. There were no statistically significant differences for mortality or ICU admission. Significantly lower mortality was seen with high..Jan 31Details Source PDF Late treatment studyLate treatment studyReducing length of hospital stay with colchicineKarakaş et al., The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924Retrospective 356 hospitalized COVID-19 patients, shorter hospitalization time with colchicine treatment. There were no statistically significant differences for mortality or ICU admission. Significantly lower mortality was seen with higher dosage (1mg/day vs 0.5mg/day). More control patients were on oxygen at baseline (65% vs. 54%).risk of death, 12.7% lower, RR 0.87, p = 0.72, treatment 16 of 165 (9.7%), control 19 of 171 (11.1%), NNT 71.risk of ICU admission, 16.0% lower, RR 0.84, p = 0.50, treatment 30 of 165 (18.2%), control 37 of 171 (21.6%), NNT 29.hospitalization time, 25.0% lower, relative time 0.75, p < 0.001, treatment 165, control 171.Excluded in after exclusion results of meta analysis:excessive unadjusted differences between groups.Karakaş et al., 1/31/2022, retrospective, Turkey, Europe, peer-reviewed, 11 authors.Share Tweet Submit Corrections or CommentsJan 28PrEPPEPTopless et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-Xdeath, ↓23.2%, p=0.12Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based studyDetails UK Biobank retrospective showing a higher risk of COVID-19 cases and mortality for patients with gout. Among patients with gout, mortality risk was lower for those on colchicine, OR 1.06 [0.60-1.89], compared to those without colchicine, ..Jan 28Details Source PDF Prophylaxis studyProphylaxis studyGout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based studyTopless et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-XUK Biobank retrospective showing a higher risk of COVID-19 cases and mortality for patients with gout. Among patients with gout, mortality risk was lower for those on colchicine, OR 1.06 [0.60-1.89], compared to those without colchicine, OR 1.38 [1.08-1.76].risk of death, 23.2% lower, OR 0.77, p = 0.12, relative odds for patients with gout, model 2, RR approximated with OR.Topless et al., 1/28/2022, retrospective, database analysis, United Kingdom, Europe, peer-reviewed, 6 authors.Share Tweet Submit Corrections or CommentsJan 12MetaZein et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2022.102395 (meta analysis)meta-analysisEffect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysisDetails Systematic review and meta analysis showing that colchicine was associated with lower mortality in COVID-19 patients: All studies: RR 0.66 [95%CI 0.53, 0.83], p < 0.001; I2: 42% RCTs: RR 0.81 [95%CI 0.54, 1.20], p = 0.29; I2: 10% The RCT ..Jan 12Details Source PDF MetaMetaEffect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysisZein et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2022.102395 (meta analysis)Systematic review and meta analysis showing that colchicine was associated with lower mortality in COVID-19 patients:All studies: RR 0.66 [95%CI 0.53, 0.83], p < 0.001; I2: 42%
RCTs: RR 0.81 [95%CI 0.54, 1.20], p = 0.29; I2: 10%The RCT result is non-significant, but is highly affected by the very late stage RECOVERY trial, which is not generalizable to earlier usage.Zein et al., 1/12/2022, peer-reviewed, 2 authors.Share Tweet Submit Corrections or CommentsJan 8PrEPPEPMonserrat Villatoro et al., Pharmaceuticals, doi:10.3390/ph15010078death, ↓80.0%, p=0.02A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching AnalysisDetails PSM retrospective 3,712 hospitalized patients in Spain, showing lower mortality with existing use of azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine..Jan 8Details Source PDF Prophylaxis studyProphylaxis studyA Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching AnalysisMonserrat Villatoro et al., Pharmaceuticals, doi:10.3390/ph15010078PSM retrospective 3,712 hospitalized patients in Spain, showing lower mortality with existing use of azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine theophylline acetate, oral rehydration salts, and salbutamol sulphate, and higher mortality with acetylsalicylic acid, digoxin, folic acid, mirtazapine, linagliptin, enalapril, atorvastatin, and allopurinol.risk of death, 80.0% lower, OR 0.20, p = 0.02, RR approximated with OR.Monserrat Villatoro et al., 1/8/2022, retrospective, propensity score matching, Spain, Europe, peer-reviewed, 18 authors.Share Tweet Submit Corrections or CommentsDec 31
2021LateAlsultan et al., Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2021/2129006death, ↓35.7%, p=0.70Efficacy of Colchicine and Budesonide in Improvement Outcomes of Patients with Coronavirus Infection 2019 in Damascus, Syria: A Randomized Control TrialDetails Small RCT 49 severe condition hospitalized patients in Syria, showing lower mortality with colchicine and shorter hospitalization time with both colchicine and budesonide (all of these were not statistically significant).Dec 31
2021Details Source PDF Late treatment studyLate treatment studyEfficacy of Colchicine and Budesonide in Improvement Outcomes of Patients with Coronavirus Infection 2019 in Damascus, Syria: A Randomized Control TrialAlsultan et al., Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2021/2129006Small RCT 49 severe condition hospitalized patients in Syria, showing lower mortality with colchicine and shorter hospitalization time with both colchicine and budesonide (all of these were not statistically significant).risk of death, 35.7% lower, RR 0.64, p = 0.70, treatment 3 of 14 (21.4%), control 7 of 21 (33.3%), NNT 8.4.hospitalization time, 20.0% lower, relative time 0.80, treatment 14, control 21.Alsultan et al., 12/31/2021, Randomized Controlled Trial, Syria, Middle East, peer-reviewed, 11 authors.Share Tweet Submit Corrections or CommentsDec 29
2021LateDiaz et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.41328death, ↓12.0%, p=0.30Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19Details Very late stage RCT (O2 88%, 84% on oxygen) with 1,279 hospitalized patients in Argentina, showing lower mortality and lower combined mortality/ventilation, statistically significant only for the combined outcome and per-protocol analysis..Dec 29
2021Details Source PDF Late treatment studyLate treatment studyEffect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19Diaz et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.41328Very late stage RCT (O2 88%, 84% on oxygen) with 1,279 hospitalized patients in Argentina, showing lower mortality and lower combined mortality/ventilation, statistically significant only for the combined outcome and per-protocol analysis. NCT04328480. COLCOVID.risk of death, 12.0% lower, HR 0.88, p = 0.30, treatment 131 of 640 (20.5%), control 142 of 639 (22.2%), NNT 57, adjusted, Cox proportional hazards, primary outcome.risk of death/intubation, 17.0% lower, HR 0.83, p = 0.08, treatment 160 of 640 (25.0%), control 184 of 639 (28.8%), NNT 26, adjusted, Cox proportional hazards, primary outcome.risk of death/intubation, 52.0% lower, HR 0.48, p = 0.60, treatment 6 of 93 (6.5%), control 13 of 102 (12.7%), NNT 16, adjusted, subset not on supplemental oxygen, Cox proportional hazards.risk of death, 17.0% lower, HR 0.83, p = 0.30, treatment 98 of 515 (19.0%), control 140 of 634 (22.1%), NNT 33, adjusted, PP, Cox proportional hazards.risk of death/intubation, 25.0% lower, HR 0.75, p = 0.02, treatment 117 of 515 (22.7%), control 181 of 634 (28.5%), NNT 17, adjusted, PP, Cox proportional hazards.Excluded in after exclusion results of meta analysis:very late stage, oxygen saturation <90% at baseline.Diaz et al., 12/29/2021, Randomized Controlled Trial, Argentina, South America, peer-reviewed, 101 authors, study period 17 April, 2020 - 28 March, 2021, trial NCT04328480.Share Tweet Submit Corrections or CommentsSep 23
2021LateDorward et al., British Journal of General Practice, doi:10.3399/BJGP.2022.0083 (preprint 9/23/2021)death, ↓69.7%, p=0.43Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trialDetails Late treatment RCT with 156 colchicine patients in the UK, showing no significant differences. ISRCTN86534580.Sep 23
2021Details Source PDF Late treatment studyLate treatment studyColchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trialDorward et al., British Journal of General Practice, doi:10.3399/BJGP.2022.0083 (preprint 9/23/2021)Late treatment RCT with 156 colchicine patients in the UK, showing no significant differences. ISRCTN86534580.risk of death, 69.7% lower, RR 0.30, p = 0.43, treatment 0 of 156 (0.0%), control 1 of 120 (0.8%), NNT 120, relative risk is not 0 because of continuity correction due to zero events.risk of death/hospitalization, 29.8% higher, RR 1.30, p = 0.66, treatment 6 of 156 (3.8%), control 4 of 133 (3.0%), OR converted to RR, concurrent randomisation.risk of death/hospitalization, 22.1% lower, RR 0.78, p = 0.59, treatment 6 of 156 (3.8%), control 119 of 1,145 (10.4%), OR converted to RR, including control patients before the colchicine arm started.risk of no recovery, 6.4% higher, HR 1.06, p = 0.67, treatment 156, control 133, time to alleviation of symptoms, concurrent randomisation.Dorward et al., 9/23/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 21 authors, study period 4 March, 2021 - 26 May, 2021, average treatment delay 6.0 days.Share Tweet Submit Corrections or CommentsSep 11
2021LatePascual-Figal et al., International Journal of General Medicine, doi:10.2147/IJGM.S329810death, ↓80.2%, p=0.24Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)Details RCT with 52 colchicine patients and 51 control patients, showing lower risk of clinical deterioration with treatment. COL-COVID. NCT04350320.Sep 11
2021Details Source PDF Late treatment studyLate treatment studyColchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)Pascual-Figal et al., International Journal of General Medicine, doi:10.2147/IJGM.S329810RCT with 52 colchicine patients and 51 control patients, showing lower risk of clinical deterioration with treatment. COL-COVID. NCT04350320.risk of death, 80.2% lower, RR 0.20, p = 0.24, treatment 0 of 52 (0.0%), control 2 of 51 (3.9%), NNT 26, relative risk is not 0 because of continuity correction due to zero events.risk of mechanical ventilation, 80.2% lower, RR 0.20, p = 0.24, treatment 0 of 52 (0.0%), control 2 of 51 (3.9%), NNT 26, relative risk is not 0 because of continuity correction due to zero events.risk of ICU admission, 51.0% lower, RR 0.49, p = 0.44, treatment 2 of 52 (3.8%), control 4 of 51 (7.8%), NNT 25.risk of 7-point scale, 87.5% lower, RR 0.13, p = 0.03, treatment 3 of 52 (5.8%), control 7 of 51 (13.7%), adjusted, OR converted to RR, deterioration ≥1 point, multivariable, primary outcome.risk of 7-point scale, 80.2% lower, RR 0.20, p = 0.24, treatment 0 of 52 (0.0%), control 2 of 51 (3.9%), NNT 26, relative risk is not 0 because of continuity correction due to zero events, deterioration ≥2 points.hospitalization time, 14.6% higher, relative time 1.15, p = 0.34, treatment 52, control 51.Pascual-Figal et al., 9/11/2021, Randomized Controlled Trial, Spain, Europe, peer-reviewed, 14 authors, study period 30 April, 2020 - 4 December, 2020, trial NCT04350320.Share Tweet Submit Corrections or CommentsNov 9
2021LateAbsalón-Aguilar et al., Journal of General Internal Medicine, doi:10.1007/s11606-021-07203-8death, ↓28.6%, p=0.74Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)Details Very late stage RCT with 56 colchicine and 60 control patients in Mexico, showing no significant differences.Nov 9
2021Details Source PDF Late treatment studyLate treatment studyColchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)Absalón-Aguilar et al., Journal of General Internal Medicine, doi:10.1007/s11606-021-07203-8Very late stage RCT with 56 colchicine and 60 control patients in Mexico, showing no significant differences.risk of death, 28.6% lower, RR 0.71, p = 0.74, treatment 4 of 56 (7.1%), control 6 of 60 (10.0%), NNT 35.progression to critical or death, 17.0% lower, OR 0.83, p = 0.67, treatment 56, control 60, primary outcome, RR approximated with OR.risk of no recovery, 13.0% higher, RR 1.13, p = 0.59, treatment 56, control 60, Kaplan–Meier.Absalón-Aguilar et al., 11/9/2021, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, North America, peer-reviewed, 18 authors.Share Tweet Submit Corrections or CommentsJul 10
2021LateGaitán-Duarte et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.101242death, ↓22.0%, p=0.38Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trialDetails RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, not showing statistically significant differences in outcomes. Improved results were seen with the combination of emtricitabine/tenofovir disoproxil + ..Jul 10
2021Details Source PDF Late treatment studyLate treatment studyEffectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trialGaitán-Duarte et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.101242RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, not showing statistically significant differences in outcomes. Improved results were seen with the combination of emtricitabine/tenofovir disoproxil + rosuvastatin + colchicine. NCT04359095.risk of death, 22.0% lower, HR 0.78, p = 0.38, treatment 22 of 153 (14.4%), control 28 of 161 (17.4%), NNT 33, adjusted, Cox proportional hazards.Gaitán-Duarte et al., 7/10/2021, Randomized Controlled Trial, Colombia, South America, peer-reviewed, 17 authors, average treatment delay 10.0 days, this trial uses multiple treatments in the treatment arm (combined with rosuvastatin) - results of individual treatments may vary, trial NCT04359095.Share Tweet Submit Corrections or CommentsJun 30
2021LateKevorkian et al., Journal of Infection, doi:10.1016/j.jinf.2021.02.008progression, ↓95.7%, p=0.0005Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort studyDetails Observational study in France with 28 hospitalized patients treated with prednisone/furosemide/colchicine/salicylate/direct anti-Xa inhibitor, and 40 control patients, showing lower combined mortality, ventilation, or high-flow oxygen the..Jun 30
2021Details Source PDF Late treatment studyLate treatment studyOral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort studyKevorkian et al., Journal of Infection, doi:10.1016/j.jinf.2021.02.008Observational study in France with 28 hospitalized patients treated with prednisone/furosemide/colchicine/salicylate/direct anti-Xa inhibitor, and 40 control patients, showing lower combined mortality, ventilation, or high-flow oxygen therapy with treatment.risk of mortality, ventilation, or high-flow oxygen therapy, 95.7% lower, OR 0.04, p < 0.001, treatment 28, control 40, adjusted, multivariable, RR approximated with OR.Kevorkian et al., 6/30/2021, retrospective, France, Europe, peer-reviewed, 11 authors, study period 9 January, 2020 - 30 November, 2020, this trial uses multiple treatments in the treatment arm (combined with prednisone, furosemide, salicylate, direct anti-Xa inhibitor) - results of individual treatments may vary.Share Tweet Submit Corrections or CommentsJun 10
2021LateHueda-Zavaleta et al., Revista Peruana de Medicina Experimental y Salud Pública, doi:10.17843/rpmesp.2021.382.7158death, ↓54.0%, p=0.03Factores asociados a la muerte por COVID-19 en pacientes admitidos en un hospital público en Tacna, PerúDetails Retrospective 450 late stage (median oxygen saturation 86%) COVID+ hospitalized patients in Peru, showing lower mortality with colchicine treatment.Jun 10
2021Details Source PDF Late treatment studyLate treatment studyFactores asociados a la muerte por COVID-19 en pacientes admitidos en un hospital público en Tacna, PerúHueda-Zavaleta et al., Revista Peruana de Medicina Experimental y Salud Pública, doi:10.17843/rpmesp.2021.382.7158Retrospective 450 late stage (median oxygen saturation 86%) COVID+ hospitalized patients in Peru, showing lower mortality with colchicine treatment.risk of death, 54.0% lower, HR 0.46, p = 0.03, treatment 10 of 50 (20.0%), control 109 of 301 (36.2%), NNT 6.2, adjusted, multivariable.Hueda-Zavaleta et al., 6/10/2021, retrospective, Peru, South America, peer-reviewed, 6 authors.Share Tweet Submit Corrections or CommentsMay 18
2021LateRecovery Collaborative Group, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00435-5 (preprint 5/18/2021)death, ↑1.0%, p=0.77Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialDetails RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, median 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none&..May 18
2021Details Source PDF Late treatment studyLate treatment studyColchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialRecovery Collaborative Group, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00435-5 (preprint 5/18/2021)RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, median 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none"). ISRCTN 50189673. NCT04381936.risk of death, 1.0% higher, RR 1.01, p = 0.77, treatment 1,173 of 5,610 (20.9%), control 1,190 of 5,730 (20.8%).risk of mechanical ventilation, 18.0% higher, RR 1.18, p = 0.06, treatment 259 of 3,815 (6.8%), control 228 of 3,962 (5.8%).risk of death/intubation, 2.0% higher, RR 1.02, p = 0.47, treatment 1,344 of 5,342 (25.2%), control 1,343 of 5,469 (24.6%).risk of no hospital discharge, 2.0% higher, RR 1.02, p = 0.44, treatment 1,709 of 5,610 (30.5%), control 1,698 of 5,730 (29.6%).Recovery Collaborative Group et al., 5/18/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 35 authors, average treatment delay 9.0 days, trial NCT04381936.Share Tweet Submit Corrections or CommentsApr 20
2021LateMostafaie et al., ClinicalTrials.gov, NCT04392141 (Preprint)death, ↓83.3%, p=0.11Colchicine Plus Phenolic Monoterpenes to Treat COVID-19Details RCT with 60 patients treated with colchicine and phenolic monoterpenes and 60 control patients in Iran, showing lower mortality with treatment. NCT04392141.Apr 20
2021Details Source PDF Late treatment studyLate treatment studyColchicine Plus Phenolic Monoterpenes to Treat COVID-19Mostafaie et al., ClinicalTrials.gov, NCT04392141 (Preprint)RCT with 60 patients treated with colchicine and phenolic monoterpenes and 60 control patients in Iran, showing lower mortality with treatment. NCT04392141.risk of death, 83.3% lower, RR 0.17, p = 0.11, treatment 1 of 60 (1.7%), control 6 of 60 (10.0%), NNT 12, primary outcome.hospitalization time, 34.7% lower, relative time 0.65, p < 0.001, treatment 59, control 54.Mostafaie et al., 4/20/2021, Randomized Controlled Trial, Iran, Middle East, preprint, 1 author, this trial uses multiple treatments in the treatment arm (combined with phenolic monoterpenes) - results of individual treatments may vary, trial NCT04392141.Share Tweet Submit Corrections or CommentsMar 24
2021LateManenti et al., PLOS ONE, doi:10.1371/journal.pone.0248276death, ↓76.0%, p=0.005Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational studyDetails IPTW retrospective 141 COVID-19 patients (83% hospitalized), 71 treated with colchicine and 70 matched control patients, showing lower mortality and faster recovery with treatment.Mar 24
2021Details Source PDF Late treatment studyLate treatment studyReduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational studyManenti et al., PLOS ONE, doi:10.1371/journal.pone.0248276IPTW retrospective 141 COVID-19 patients (83% hospitalized), 71 treated with colchicine and 70 matched control patients, showing lower mortality and faster recovery with treatment.risk of death, 76.0% lower, HR 0.24, p = 0.005, treatment 71, control 70, adjusted, propensity score weighting.risk of no recovery, 44.4% lower, RR 0.56, p = 0.048, treatment 71, control 70, adjusted, propensity score weighting.Manenti et al., 3/24/2021, retrospective, Italy, Europe, peer-reviewed, 24 authors, study period 1 March, 2020 - 10 April, 2020.Share Tweet Submit Corrections or CommentsMar 14
2021MetaHariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488 (meta analysis)meta-analysisColchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysisDetails Meta analysis concluding that colchicine can reduce severity and mortality in COVID‐19 patients, mortality OR 0.43 [0.32-0.58].Mar 14
2021Details Source PDF MetaMetaColchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysisHariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488 (meta analysis)Meta analysis concluding that colchicine can reduce severity and mortality in COVID‐19 patients, mortality OR 0.43 [0.32-0.58].Hariyanto et al., 3/14/2021, peer-reviewed, 5 authors.Share Tweet Submit Corrections or CommentsMar 6
2021LateGarcía-Posada et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.02.013death, ↓56.9%, p=0.01Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian CaribbeanDetails Retrospective 209 hospitalized patients in Colombia, showing lower mortality with antibiotics + LMWH + corticosteroids + colchicine in multivariable analysis.Mar 6
2021Details Source PDF Late treatment studyLate treatment studyClinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian CaribbeanGarcía-Posada et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.02.013Retrospective 209 hospitalized patients in Colombia, showing lower mortality with antibiotics + LMWH + corticosteroids + colchicine in multivariable analysis.risk of death, 56.9% lower, RR 0.43, p = 0.01, treatment 48 of 99 (48.5%), control 59 of 110 (53.6%), adjusted, OR converted to RR, multivariable.García-Posada et al., 3/6/2021, retrospective, Colombia, South America, peer-reviewed, 8 authors, this trial uses multiple treatments in the treatment arm (combined with antibiotics, LMWH, and corticosteroidsPERIOD:5/20-8/20) - results of individual treatments may vary.Share Tweet Submit Corrections or CommentsFeb 28
2021LateMareev et al., Kardiologiia, doi:10.18087/cardio.2021.2.n1560death, ↓79.6%, p=0.49Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT studyDetails Small trial with 21 colchicine patients and 22 control patients in Russia, showing improved recovery with treatment. The trial was originally an RCT, however randomization to the control arm was stopped after 5 patients, and 17 retrospect..Feb 28
2021Details Source PDF Late treatment studyLate treatment studyProactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT studyMareev et al., Kardiologiia, doi:10.18087/cardio.2021.2.n1560Small trial with 21 colchicine patients and 22 control patients in Russia, showing improved recovery with treatment. The trial was originally an RCT, however randomization to the control arm was stopped after 5 patients, and 17 retrospective patients were added for comparison.risk of death, 79.6% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 22 (9.1%), NNT 11, relative risk is not 0 because of continuity correction due to zero events.ΔSHOCS-COVID, 50.0% lower, RR 0.50, p = 0.06, treatment 21, control 22, ΔSHOCS-COVID score, primary outcome.SHOCS-COVID, 71.4% lower, RR 0.29, p = 0.002, treatment 21, control 22, SHOCS-COVID score.NEWS-2, 66.7% lower, RR 0.33, p = 0.06, treatment 21, control 22, NEWS-2 score.hospitalization time, 25.7% lower, relative time 0.74, p = 0.08, treatment 21, control 22.Mareev et al., 2/28/2021, retrospective, Russia, Europe, peer-reviewed, 21 authors.Share Tweet Submit Corrections or CommentsJan 27
2021LateTardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (preprint 1/27)death, ↓43.9%, p=0.30Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trialDetails RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682.Jan 27
2021Details Source PDF Late treatment studyLate treatment studyColchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trialTardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (preprint 1/27)RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682.risk of death, 43.9% lower, RR 0.56, p = 0.30, treatment 5 of 2,235 (0.2%), control 9 of 2,253 (0.4%), NNT 569, OR converted to RR.risk of death/hospitalization, 20.0% lower, RR 0.80, p = 0.08, treatment 104 of 2,235 (4.7%), control 131 of 2,253 (5.8%), NNT 86, OR converted to RR, primary outcome.risk of mechanical ventilation, 46.8% lower, RR 0.53, p = 0.09, treatment 11 of 2,235 (0.5%), control 21 of 2,253 (0.9%), NNT 227, OR converted to RR.risk of hospitalization, 20.0% lower, RR 0.80, p = 0.09, treatment 101 of 2,235 (4.5%), control 128 of 2,253 (5.7%), NNT 86, OR converted to RR.Tardif et al., 1/27/2021, Double Blind Randomized Controlled Trial, Canada, North America, peer-reviewed, 44 authors, average treatment delay 5.3 days, trial NCT04322682.Share Tweet Submit Corrections or CommentsJan 7
2021LateValerio Pascua et al., PLOS ONE, doi:10.1371/journal.pone.0245025death, ↓22.8%, p=0.60A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patientsDetails Retrospective 65 ICU patients in the USA and Honduras, showing shorter ICU stay with combined treatment including colchicine, LMWH, tocilizumab, dexamethasone, and methylprednisolone.Jan 7
2021Details Source PDF Late treatment studyLate treatment studyA multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patientsValerio Pascua et al., PLOS ONE, doi:10.1371/journal.pone.0245025Retrospective 65 ICU patients in the USA and Honduras, showing shorter ICU stay with combined treatment including colchicine,
LMWH, tocilizumab, dexamethasone, and methylprednisolone.risk of death, 22.8% lower, RR 0.77, p = 0.60, treatment 5 of 35 (14.3%), control 12 of 30 (40.0%), NNT 3.9, adjusted, OR converted to RR, multivariable.ICU time, 39.9% lower, relative time 0.60, p = 0.03, treatment 35, control 30, adjusted, multivariable.Valerio Pascua et al., 1/7/2021, retrospective, multiple countries, multiple regions, peer-reviewed, 19 authors, study period 10 June, 2020 - 6 August, 2020, average treatment delay 6.1 days, this trial uses multiple treatments in the treatment arm (combined with LMWH, tocilizumab, dexamethasone, methylprednisolone) - results of individual treatments may vary.Share Tweet Submit Corrections or CommentsDec 31
2020LateMahale et al., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-23599death, ↑7.2%, p=0.83A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care HospitalDetails Retrospective 134 hospitalized COVID-19 patients in India, showing no significant difference with colchicine treatment in unadjusted results.Dec 31
2020Details Source PDF Late treatment studyLate treatment studyA Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care HospitalMahale et al., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-23599Retrospective 134 hospitalized COVID-19 patients in India, showing no significant difference with colchicine treatment in unadjusted results.risk of death, 7.2% higher, RR 1.07, p = 0.83, treatment 11 of 39 (28.2%), control 25 of 95 (26.3%).Excluded in after exclusion results of meta analysis:unadjusted results with no group details.Mahale et al., 12/31/2020, retrospective, India, South Asia, peer-reviewed, 22 authors, study period 22 March, 2020 - 21 May, 2020.Share Tweet Submit Corrections or CommentsNov 5
2020LateRodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomesdeath, ↓5.5%, p=0.87Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort studyDetails Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely.Nov 5
2020Details Source PDF Late treatment studyLate treatment studyClinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort studyRodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & OutcomesRetrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely.risk of death, 5.5% lower, RR 0.94, p = 0.87, treatment 16 of 52 (30.8%), control 85 of 261 (32.6%), NNT 56, unadjusted.Excluded in after exclusion results of meta analysis:substantial unadjusted confounding by indication likely, excessive unadjusted differences between groups, unadjusted results with no group details.Rodriguez-Nava et al., 11/5/2020, retrospective, USA, North America, peer-reviewed, median age 68.0, 8 authors.Share Tweet Submit Corrections or CommentsOct 27
2020LateSandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954death, ↓41.7%, p=0.0006A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 InfectionDetails Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.Oct 27
2020Details Source PDF Late treatment studyLate treatment studyA Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 InfectionSandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.risk of death, 41.7% lower, RR 0.58, p < 0.001, treatment 16 of 34 (47.1%), control 63 of 78 (80.8%), NNT 3.0.risk of mechanical ventilation, 52.9% lower, RR 0.47, p < 0.001, treatment 16 of 34 (47.1%), control 68 of 68 (100.0%), NNT 1.9.risk of no hospital discharge, 41.7% lower, RR 0.58, p < 0.001, treatment 16 of 34 (47.1%), control 63 of 78 (80.8%), NNT 3.0.hospitalization time, 4.5% lower, relative time 0.95, treatment 34, control 78.Sandhu et al., 10/27/2020, prospective, USA, North America, peer-reviewed, 4 authors.Share Tweet Submit Corrections or CommentsOct 23
2020LatePinzón et al., Research Square, doi:10.21203/rs.3.rs-94922/v1 (Preprint)death, ↓34.5%, p=0.18Clinical Outcome of Patients with COVID-19 Pneumonia Treated with Corticosteroids and Colchicine in ColombiaDetails Retrospective 301 pneumonia patients in Colombia showing lower mortality with colchicine treatment.Oct 23
2020Details Source PDF Late treatment studyLate treatment studyClinical Outcome of Patients with COVID-19 Pneumonia Treated with Corticosteroids and Colchicine in ColombiaPinzón et al., Research Square, doi:10.21203/rs.3.rs-94922/v1 (Preprint)Retrospective 301 pneumonia patients in Colombia showing lower mortality with colchicine treatment.risk of death, 34.5% lower, RR 0.65, p = 0.18, treatment 14 of 145 (9.7%), control 23 of 156 (14.7%), NNT 20, OR converted to RR.Pinzón et al., 10/23/2020, retrospective, Colombia, South America, preprint, 9 authors.Share Tweet Submit Corrections or CommentsSep 21
2020LateSalehzadeh et al., Research Square, doi:10.21203/rs.3.rs-69374/v1 (Preprint)hosp. time, ↓22.7%, p=0.001The Impact of Colchicine on The COVID-19 Patients; A Clinical Trial StudyDetails Open label RCT with 100 hospitalized patients in Iran, 50 treated with colchicine, showing shorter hospitalization time. There were no deaths. IRCT20200418047126N1.Sep 21
2020Details Source PDF Late treatment studyLate treatment studyThe Impact of Colchicine on The COVID-19 Patients; A Clinical Trial StudySalehzadeh et al., Research Square, doi:10.21203/rs.3.rs-69374/v1 (Preprint)Open label RCT with 100 hospitalized patients in Iran, 50 treated with colchicine, showing shorter hospitalization time. There were no deaths. IRCT20200418047126N1.hospitalization time, 22.7% lower, relative time 0.77, p = 0.001, treatment 50, control 50.Salehzadeh et al., 9/21/2020, Randomized Controlled Trial, Iran, Middle East, preprint, 3 authors.Share Tweet Submit Corrections or CommentsSep 14
2020LateScarsi et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712death, ↓84.9%, p<0.0001Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndromeDetails Retrospective 122 colchicine patients and 140 control patients in Italy, showing lower mortality with treatment.Sep 14
2020Details Source PDF Late treatment studyLate treatment studyAssociation between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndromeScarsi et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712Retrospective 122 colchicine patients and 140 control patients in Italy, showing lower mortality with treatment.risk of death, 84.9% lower, HR 0.15, p < 0.001, treatment 122, control 140.Scarsi et al., 9/14/2020, retrospective, Italy, Europe, peer-reviewed, 28 authors.Share Tweet Submit Corrections or CommentsSep 14
2020LateBrunetti et al., J. Clin. Med., 9:9, 2961, doi:10.3390/jcm9092961death, ↓72.7%, p=0.03Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19Details PSM matched analysis from consecutive hospitalized patients, with 33 colchicine and 33 control matched patients, showing lower mortality with treatment.Sep 14
2020Details Source PDF Late treatment studyLate treatment studyColchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19Brunetti et al., J. Clin. Med., 9:9, 2961, doi:10.3390/jcm9092961PSM matched analysis from consecutive hospitalized patients, with 33 colchicine and 33 control matched patients, showing lower mortality with treatment.risk of death, 72.7% lower, RR 0.27, p = 0.03, treatment 3 of 33 (9.1%), control 11 of 33 (33.3%), NNT 4.1, PSM.risk of no hospital discharge, 72.7% lower, RR 0.27, p = 0.03, treatment 3 of 33 (9.1%), control 11 of 33 (33.3%), NNT 4.1, PSM.Brunetti et al., 9/14/2020, retrospective, propensity score matching, USA, North America, peer-reviewed, 7 authors.Share Tweet Submit Corrections or CommentsAug 12
2020LateLopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (preprint 8/12)death, ↓80.0%, p=0.49Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trialDetails RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.Aug 12
2020Details Source PDF Late treatment studyLate treatment studyBeneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trialLopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (preprint 8/12)RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.risk of death, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 36 (0.0%), control 2 of 36 (5.6%), NNT 18, relative risk is not 0 because of continuity correction due to zero events.risk of ICU admission, 50.0% lower, RR 0.50, p = 0.67, treatment 2 of 36 (5.6%), control 4 of 36 (11.1%), NNT 18.hospitalization time, 22.2% lower, relative time 0.78, p < 0.01, treatment 36, control 36.Lopes et al., 8/12/2020, Double Blind Randomized Controlled Trial, Brazil, South America, peer-reviewed, 34 authors, average treatment delay 9.5 (treatment) 8.0 (control) days.Share Tweet Submit Corrections or CommentsJun 24
2020LateDeftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136death, ↓77.3%, p=0.19Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical TrialDetails RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment. NCT04326790.Jun 24
2020Details Source PDF Late treatment studyLate treatment studyEffect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical TrialDeftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment. NCT04326790.risk of death, 77.3% lower, RR 0.23, p = 0.19, treatment 1 of 55 (1.8%), control 4 of 50 (8.0%), NNT 16.risk of mechanical ventilation, 81.8% lower, RR 0.18, p = 0.10, treatment 1 of 55 (1.8%), control 5 of 50 (10.0%), NNT 12.risk of clinical deterioration, 87.4% lower, RR 0.13, p = 0.046, treatment 1 of 55 (1.8%), control 7 of 50 (14.0%), NNT 8.2, OR converted to RR.Deftereos et al., 6/24/2020, Randomized Controlled Trial, Greece, Europe, peer-reviewed, 49 authors, trial NCT04326790.Share Tweet Submit Corrections or CommentsPlease send us corrections, updates, or comments. Vaccines andtreatments are both valuable and complementary. All practical, effective, andsafe means should be used. No treatment, vaccine, or intervention is 100%available and effective for all current and future variants. Denying theefficacy of any method increases mortality, morbidity, collateral damage, andthe risk of endemic status. We do not provide medical advice. Before takingany medication, consult a qualified physician who can provide personalizedadvice and details of risks and benefits based on your medical history andsituation. FLCCC and WCHprovide treatment protocols. Thanks for your feedback! Please search before submitting papers and notethat studies are listed under the date they were first available, which may bethe date of an earlier preprint.SubmitShareTweet@CovidAnalysisFAQPublic domain CC0 1.0

TAGS:real COVID Colchicine for

<<< Thank you for your visit >>>

Hot Websites